Nuvation Bio Inc. is trading at $4.88 (5.5% down) today, giving back a portion of its sharp gains following a recent bullish analyst call.
- RBC Capital recently reiterated an Outperform rating and raised its price target to $20, citing significant optimism surrounding the company's glioma drug candidate.
- The stock is currently facing downward pressure amid a broader risk-off environment affecting the biotechnology and growth sectors.